# Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

> **NCT03360747** · PHASE2 · COMPLETED · sponsor: **Akcea Therapeutics** · enrollment: 3 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome
- Lipoprotein Lipase Deficiency
- Hyperlipoproteinemia Type 1

## Interventions

- **DRUG:** AKCEA-ANGPTL3-LRx

## Key facts

- **NCT ID:** NCT03360747
- **Lead sponsor:** Akcea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-21
- **Primary completion:** 2018-06-12
- **Final completion:** 2018-09-04
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2021-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03360747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03360747, "Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03360747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*